Targeted radiation zaps stubborn blood cancer in new trial
NCT ID NCT05363111
Summary
This early-stage trial is testing a new combination treatment for multiple myeloma that has come back or stopped responding to standard therapies. It combines a standard antibody drug with a radioactive version designed to deliver radiation directly to cancer cells. The main goals are to find the safest and most effective dose and to see if this approach can help control the disease in patients who have run out of other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.